Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...
Many potential drug candidates fail to advance because of a lack of clinical activity at tolerated doses or because of unmanageable toxicities. Other limitations include a deficit of drug-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback